#12nd HALF 2021 INVESTOR PRESENTATION POLYPEPTIDE GROUP HN- H₂N NH HN HN= NH NH HN NH GLOBAL SUPPORT FOR A QUALITY SOLUTION NH2 HN- H HN NH2 HN HO PolyPeptide GROUP THE ULTIMATE PEPTIDE PARTNER#2Disclaimer This presentation (the "Presentation") has been prepared by PolyPeptide Group AG ("PolyPeptide" and together with its subsidiaries, "we", "us" or the "Group"). The information contained in the Presentation does not purport to be comprehensive. Please refer to the financial reports available on our website at https://report.polypeptide.com/hyr/21. PolyPeptide, together with its directors, officers, employees and advisors, make no representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the fairness, reasonableness, accuracy, or completeness or correctness of the information contained in the Presentation or of the views given or implied. PolyPeptide, together with its directors, officers, employees and advisors, shall have no liability whatsoever for any errors or omissions or any loss howsoever arising, directly or indirectly, from any use of this Presentation, its information or its contents or otherwise arising in connection therewith. PolyPeptide reserves the right to amend or replace the Presentation at any time, and undertakes no obligation to provide the recipients with access to any additional information. Neither PolyPeptide, its directors, officers, employees or advisors nor any other person shall not be obligated to update or correct the information set forth in the Presentation (except as required by applicable laws and regulations). Nothing in this Presentation is, or should be relied upon as, a promise or representation as to the future. To the extent available, the industry, market and competitive position data contained in this Presentation has come from official or third-party sources as of at 31 December 2020. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Group believes that each of these publications, studies and surveys has been prepared by a reputable source, the Group has not independently verified the data contained therein and there is no guarantee that such data has been verified by those sources. In addition, certain of the industry, market and competitive position data contained in this Presentation come from the Group's own internal research and estimates based on the knowledge and experience of the Group's management in the market in which the Group operates. While the Group believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in this Presentation. Unaudited Financial Results The financial information contained in this Presentation is unaudited. Forward-looking information This Presentation has been prepared by PolyPeptide and includes forward-looking information and statements concerning the outlook for its business. These statements are based on current expectations, estimates and projections about the factors that may affect its future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as 'expects', 'believes', 'estimates', 'targets', 'plans', 'outlook' or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide's control, that could cause its actual results to differ materially from the forward-looking information and statements made in this Presentation and which could affect its ability to achieve its stated targets. Although PolyPeptide believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved. Alternative Financial Performance Measures (APM) This Presentation contains references to operational indicators, such as customer projects, and alternative financial performance measures ("APM") that are not defined or specified by IFRS, including EBITDA, adjusted EBITDA, adjusted EBITDA margin, net operating assets, return on net operating assets, capital expenditures, equity ratio, net working capital, free cash flow, net cash and total financial debt. These APM should be regarded as complementary information to and not as substitutes of the Group's consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, refer to the section "Definitions and reconciliations" in PolyPeptide Group AG's half-year report 2021 available at https://report.polypeptide.com/hyr/21. THIS PRESENTATION IS NOT AN INVITATION TO PURCHASE SECURITIES OF POLYPEPTIDE OR THE GROUP. GLOBAL SUPPORT FOR A QUALITY SOLUTION 2 PolyPeptide GROUP#3Content 1 Market overview 2 Company overview Page 4 Page 6 3 Value proposition & priorities Page 12 4 Performance & financial targets Page 17 5 Corporate governance GLOBAL SUPPORT FOR A QUALITY SOLUTION 3 Page 19 PolyPeptide GROUP#4Peptide-based drugs market with structural growth momentum Broad therapeutic areas with significant product pipeline Estimated peptide therapeutics end market ($ Bn)(1) 7% CAGR 42 222 39 36 34 32 21F 22F 23F 24F 2020 Based on a study conducted for PolyPeptide Notes: 1. 2. As of Dec-2020 GLOBAL SUPPORT FOR A QUALITY SOLUTION Therapeutic areas for peptide-based drugs (1) Other 30% Metabolic 24% 76 Drugs Approved (2) ~$ 32 Bn 44 Neurological 5% Cardiovascular 8% Oncology 23% 500 Drugs In Development(2) Gastrointestinal 9% 25F 4 Beneficial characteristics of peptides driving strong product pipeline and investments into R&D Expanding applications for peptide drugs ✓ Increasing incidence of cancer Rising prevalence of metabolic disorders PolyPeptide GROUP#5Addressable peptide API market of ~$ 1.2 Bn with ~10% CAGR Continued trend towards outsourcing and specialization Market structure (1) In-House 35% Industrial logic towards outsourcing Total peptide API Increasing risk mitigation by pharma companies $ 1.8 Bn market 2020 10% 20-25F CAGR (1) Outsourced 65% Total addressable market 2020 Others ~50% $ 1.2 Bn 25-30% Peer 1 PolyPeptide GROUP 20-25% Notes: 1. Based on a study conducted for PolyPeptide GLOBAL SUPPORT FOR A QUALITY SOLUTION Higher complexity of emerging peptide APIs Shift towards the use of chemical synthesis favours CDMOs over in-house pharma expertise Competitive dynamics Highly specialized technical expertise and know-how High capex requirements Long-term, sticky customer relationships Established reputation required to win major contracts Improving track record and reputation of specialized peptide CDMOS Rigorous regulatory environment Quality and reliability of supply is critical 5 PolyPeptide GROUP#6PolyPeptide with >70 years experience in peptide manufacturing Global footprint with GMP-certified sites for services across development phases Company Snapshot A global market leader for innovative clinical and commercial stage peptide drug substances Dedicated peptide API manufacturer, producing around one half of all currently approved peptide drug substances 70+ years of specialized, accumulated know-how in peptides Long-term partner from start-up to large pharmaceutical customers COMPREHENSIVE SERVICES FOR COMPLEX PEPTIDES Custom Projects Contract Manufacturing Generics & Cosmetics 1'026 GLOBAL SUPPORT FOR A QUALITY SOLUTION Network of specialized sites with experienced teams Employees by experience 40% <2 years 25% 2 to 10 years 35% >10 years Full-time equivalents as per 30 June 2021 6 Braine-l'Alleud, BE Malmö, SE Torrance, CA Zug, CH Strasbourg, FR San Diego, CA Ambernath, IN PolyPeptide GROUP#7Comprehensive services for complex peptides Supporting customers over product life cycle in three segments Description Custom Projects Contract Manufacturing Generic and Cosmetics Smaller scale, custom research-grade peptides Process designed in partnership with the customer to be scalable through the development process Expertise in process development, manufacturing scale-up, and regulatory filing builds strong customer relationships Manufacture of a range of peptide-based generics and cosmetics at commercial scale for multiple customers Development Phase Pre-clinical & Clinical GLOBAL SUPPORT FOR A QUALITY SOLUTION 7 Commercial Generics & Cosmetics PolyPeptide GROUP#8Established base of >250 customers Long-term relationships at consistent high level of customer satisfaction Customer centric approach Working in partnerships Projects continuing along life cycle Multi-site access and transferability GLOBAL SUPPORT FOR A QUALITY SOLUTION 33% Stable customer base: Duration of relationship¹) 4% 29% Customer satisfaction according to annual survey 85 84 90 88 >30y 15-29y 10-14y 5-9y 21% 13% <5y 2017 2018 2019 2020 1) 2020 top 10 customers (unaudited) revenue share in % by years of relationship. 8 PolyPeptide GROUP#9Production sites overview (1/2) Specialized facilities from experimental to large scale production Malmö Braine Strasbourg Torrance San Diego Ambernath PolyPept de Heritage of PolyPeptide. Large facility for all peptide batch sizes and all segments. ~12,800 m² Site with largest liquid phase synthesis in operations, major solid phase capacity expansion ongoing; facility for all peptide batch sizes and all segments. ~30,000 m² Special focus on innovation and cosmetics. Smaller facility for most peptide segments. ~6,100 m² Mid-sized site, also servicing personalized medicine, handling most peptide batch sizes for all segments; in process to set-up lab space and pilot GMP facility to serve oligonucleotides. ~14,000 m² Designed to efficiently handle smaller peptide batch sizes for all segments, incl. radio-labelled peptides. ~4,800 m² Designed to handle generic peptides, manufactured mostly in mid-sized batches. ~8,100 m² 65 FTE's 67 FTE's 160 FTE's >20 years >10 years 119 FTE's 344 FTE's 271 FTE's >20 years >20 years >30 years >30 years GLOBAL SUPPORT FOR A QUALITY SOLUTION 9 PolyPeptide GROUP#10Production sites overview (2/2) Mature processes to ensure regulatory compliance Other Local FDA ESG Malmö 8 approvals 1997, 2001, 2004, 2005, 2008, 2009, 2013, 2016 Braine 6 approvals Strasbourg 2001, 2005, 2009, 2012, 2014, 2017 3 approvals 2009, 2014, 2019 7 approvals 2003, 2004, 2007, 2010, 2017, 2015, 2019 2007, 2011, 2015, 2016, 2017 & 2018 2017 2005 & 2012 2009 GOLD 2020 ecovadis Sustainability Rating Torrance 14 approvals 1999, 2001, 2001, 2002, 2004, 2008, 2009, 2010, 2011, 2012, 2013, 2015, 2017, 2019 San Diego 14 approvals 1992, 1995, 1998, 2004, 2005, 2005, 2009, 2009, 2010, 2011, 2012, 2015, 2017, 2019 Ambernath 2 approvals 2016, 2019 5 approvals 5 approvals 2008, 2011, 2014, 2017, 2020 2006, 2010, 2014, 2017, 2020 1 approval (State of California) 1997 2001, 2005, 2009 2012, 2013, 2014 & 2016 2015 Notes: Approval = Attestation of acceptable facilities for cGMP manufacturing GLOBAL SUPPORT FOR A QUALITY SOLUTION 2011 2017 # 2 approvals (State of California) 1990, 2002 World Health Organization 5 approvals 2013, 2015, 2015, 2017 & 2019 2017 2011 & 2016 SILVER 2020 ecovadis Sustainability Rating SILVER 2021 ecovadis Sustainability Rating SILVER 2021 ecovadis Sustainability Rating 10 2014 2005 2012, 2016, 2019 PolyPeptide GROUP#11Revenue structure and project pipeline Innovation - excellence – trust H1 2021 revenue split (EUR 135 m) - Metabolic Gastrologic Oncologic Cardio- and neurologic Other Large pharma Biotech Other pharma & academia Custom Projects Contract Manufacturing Generics & Cosmetics # of custom projects Pre-clinical Phase I Phase II Phase III GLOBAL SUPPORT FOR A QUALITY SOLUTION Helping patients accross multiple deseases Revenue structure by therapeutic areas Servicing a diversified customer base Revenue structure by customer type Providing solutions along product phases Revenue structure by business segment Focusing on innovation Number of custom projects by stage of development 11 PolyPeptide GROUP#12Current priorities to capitalize on structural opportunities Build capacities and capabilities to meet growing demand Let's stay focused on the needs of our peptide customers One PolyPeptide Culture Let's go for growth, also exploring new avenues Providing patients with high quality medicines Let's drive innovation and technology to stay ahead GLOBAL SUPPORT FOR A QUALITY SOLUTION 12 12 PolyPeptide GROUP#13Legend: Start here - stay here Be the preferred partner across the entire peptide value chain Drug discovery & lead optimization API development & manufacturing: From early phases to commercialization Clinical development Pre-clinical research Phase I Phase II Phase III NDA filing GMP clinical batches Drug product launch Commercialisation Generization API manufacturing Non-GMP batches Scale-up batches Commercial supply PPQ batches API process & analytical development Process development Analytical method development Process validation Analytical method validation Product release & LCM Developmental stability studies and ICH stability Annual product review Regulatory support & documentation CMC documentation and filing support API - Active pharmaceutical ingredient; CMC - Chemistry, manufacturing & controls; GMP - Good manufacturing practice; ICH - International council for harmonization; LCM - Life cycle management; NDA - New drug application; PPQ - Process performance qualification GLOBAL SUPPORT FOR A QUALITY SOLUTION 13 Post approval changes PolyPeptide GROUP#14Growing and investing in our core business Committed to increasing capacity to meet customer needs Strong pipeline for peptide therapeutics with increasing commercial volume expectations... ... PolyPeptide aiming to be the preferred partner... ...resulting in commitment to increase capacity and accelerate investments across the network 181 projects under development at PolyPeptide 73 Trusted, long-term partnerships Highest quality 39 39 CLEAN 30 Committed to reliable delivery Preclinical Phase I Phase II Phase III GLOBAL SUPPORT FOR A QUALITY SOLUTION Flexible to customer needs 14 PolyPeptide GROUP#15Improving cost, time, quality Innovation is critical for staying ahead of the curve MM Increasing process & analytical performance ■ Pre-activation, washing practices ■ Alternative isolation technologies ■Flow chemistry, electrochemistry Culture of innovation • Innovation culture being embedded in the organization Global "Innovation and Technology" group in Strasbourg and Torrance Go from idea to concept all the way to deployment at scale Incubator for new business (services and product) ideas 10 10101 Digitalization & automation ■SPPS advanced monitoring and Chromatography automation ■In silico predictive tools ■MES, LIMS Established external collaborations network University of Strasbourg IBMM Institut des Biomolécules Max Mousseron ValiFluid ■ Reduction of DMF consumption ■ Green solvents Green processes ■ Mechanochemistry, recombinant RI. SE YPSO Your Process Secured & Optimized FACTO ACS Green Chemistry Institute Pharmaceutical Roundtable GLOBAL SUPPORT FOR A QUALITY SOLUTION 15 PolyPeptide GROUP#16Addressing the emerging oligonucleotides adjacent market On track to benefit from synergistic market opportunities Synergistic opportunities Commercial readiness around YE 2021 Significant interest expressed by leading customers; established customer relationships within overlapping customer bases Initialization ✓ Commercial modified oligo • • Overlapping technical and scientific expertise requirements, with quality lab space and production processes in place ✓ Customer contacts ✓ Expert team ✓ GMP documentation Oligo Lab space Team purely focused on oligonucleotide business, including senior and process scientists • Oligo Pilot GMP plant, Q4 • Oligo first customer end H2 • Modified Oligo GMP plant, Q4 Pipeline building • Build early-stage pipeline Scale-up team and infrastructure Establish track record Plan and design large- scale capacity Required scale-up and GMP manufacturing know-how, available at PolyPeptide GLOBAL SUPPORT FOR A QUALITY SOLUTION 16 2020 2021 2022 2023 2024 2025+ PolyPeptide GROUP#171H 2021 performance Strong revenue growth and operating leverage KEUR H12021 H12020 Change Revenue 135,136 87,808 53.9% Custom Projects 76,207 33,504 127.5% Contract Manufacturing 45,765 42,901 6.7% Generics & Cosmetics 13,164 11,403 15.4% EBITDA 39,889 18,519 115.4% Adjusted EBITDA 43,240 18,519 133.5% Adjusted EBITDA in % of revenue 32.0% 21.1% 10.9 ppts Operating result (EBIT) 30,803 10,160 203.2% Operating result (EBIT) in % of revenue 22.8% 11.6% 11.2 ppts Result for the period 24,623 7.831 214.4% Result for the period in % of revenue 18.2% 8.9% 9.3 ppts Earnings per share (EUR), basic 0.79 0.26 Return on net operating assets (RONOA) 25.6% 12.2% 203.6% 13.4 ppts Cash and cash equivalents (end of period) Net cash flow from operating activities 187,362 41,038 8,727 13,949 Capital expenditures 24,989 Capital expenditures in % of revenue 18.5% 9,465 10.8% Total assets (end of period) 571,950 313,888 194.2% 164.0% 7.7 ppts 82.2% 1 Adjusted EBITDA excludes one-off IPO costs of EUR 5.7 million, partly offset by US government loans of EUR 2.4 million waived in context of the coronavirus pandemic. Equity ratio (end of period) 67.4% 50.0% Employees (# of FTEs, average) 1,026 896 14.5% 17.4 ppts This table includes references to alternative financial performance measures (APM) that are not defined or specified by IFRS. These APM should be regarded as complementary information to and not as substitutes of the Group's consolidated financial results based on IFRS. For the definitions of the main operational indicators and APM used, including related abbreviations, as well as for selected reconciliations to IFRS, refer to the section "Definitions and reconciliations" in PolyPeptide Group AG's half-year report 2021. GLOBAL SUPPORT FOR A QUALITY SOLUTION 17 PolyPeptide GROUP#18Financial targets Raised guidance for full year 2021 Mid-term guidance 2021 guidance Promising structural industry trends Market position with 20-25% market share Established and long-standing customer base Strong H1 2021 performance Favorable environment, incl COVID Enhanced capacity needs Mid-term guidance unchanged Growth in low teens with adjusted EBITDA margin of around 30% GLOBAL SUPPORT FOR A QUALITY SOLUTION 18 Revenue growth Adj. EBITDA margin ~25% previously 16-18% ~32% previously ~28% Capex as % of Revenue >20% previously ~17% PolyPeptide GROUP#19Executive Committee Jan Fuhr Miller CFO Tenure start 2015 International experience across Canada, France, USA, Sweden and Denmark • Former Vice-President at CMC Biologics, Nordic Finance Leader at Honeywell and Director of Finance & Logistics at Lundbeck • Raymond De Vré CEO Tenure start April 2021 Track record in pharma, most recently as Global Head of Biologics at Dr. Reddy's Laboratories, India; former partner at McKinsey focusing on pharma, biotech, and specialty chemicals companies worldwide CEO since listing on April 29 • Jan Christensen Global Director Sales and Marketing Tenure start 2002 In position since 2010. Previous responsibilities within the Group as Director Sales Europe, Head of Global Generics and Head of Generics Europe Roles as Head of Pharma Nordic at Helm Group, Head of Chemical Department of Statoil Denmark, Sales Manager ICI Nordics and ICI Denmark GLOBAL SUPPORT FOR A QUALITY SOLUTION Daniel Lasanow Director Global Operations Tenure start 2016 • Broad background in production and technical operations within the pharma sector, including multi- • • sites Managing Director at Siegfried and BASF Pharma Production Director at Lonza Belgium and UCB Bioproducts (acquired by Lonza) 19 1999 Christina del Vecchio General Counsel & Corporate Secretary Tenure start September 2021 Previous roles as counsel with NKF, Zurich, and as associate with Latham & Watkins LLP, London Advising international corporate clients on commercial and financing transactions, securities laws, governance, compliance and other legal matters PolyPeptide GROUP#20Board of Directors Peter Wilden Chairman • Former CFO at Ferring • Former Board member of Lonza Jane Salik Member • At PolyPeptide from 1996 to 2021 • President PolyPeptide Laboratories Inc., 2006 appointed CEO Erik Schropp Member • CEO C&P Investors Group Serving on the board of various life science companies GLOBAL SUPPORT FOR A QUALITY SOLUTION Philippe Weber Independent Member • Partner at Niederer Kraft Frey • Board member of Medacta, Leonteq, Δ EDAG Engineering Group, Arbon, Banca del Ceresio • • Δ • Patrick Aebischer Independent Member Board member of Nestlé, Logitech Former board member of Lonza Former president of the Swiss Federal Institute of Technology Δ Beat In-Albon Independent Member Former Executive Vice President & COO Life Science Ingredients at Lonza • Former Executive Vice President Life Science / Industrial Services at SGS Chairman and members appointed in 2021 in context of IPO 승 Chair Member Remuneration &nomination committee Innovation & technology committee Audit & risk committee 20 20 PolyPeptide GROUP#21Analyst coverage Bank of America Patrick Wood, +44 20 7995 7035, [email protected] Berenberg Beatrice Allen, +44 20 3465 2662, [email protected] Credit Suisse Barbora Blaha, +41 44 334 60 54, Barbora. [email protected] Morgan Stanley James P. Quigley, +44 20 7677 1963, [email protected] Octavian Tanya Hansalik, +41 44 520 06 29, [email protected] Zürcher Kantonalbank Daniel Buchta, +41 44 292 37 [email protected] GLOBAL SUPPORT FOR A QUALITY SOLUTION 21 24 PolyPeptide GROUP#22Contact and IR calendar Contact Michael Stäheli Head of Investor Relations & Corporate Communications Phone: +41 (0) 41 723 20 34 [email protected] www.polypeptide.com Selected events in 2021 13-14 September 2021 | Morgan Stanley 19th Annual Global Healthcare Conference 3-5 November 2021 | ZKB Swiss Equities Conference 16-19 November 2021 | 14th Credit Suisse Equity Forum Switzerland Corporate events in 2022 15 March 2022 | FY 2021 Results 26 April 2022 | AGM 2022 GLOBAL SUPPORT FOR A QUALITY SOLUTION 22 22 PolyPeptide GROUP#23www.polypeptide.com HN H₂N HN- NH2 NH HN NH NH HN NH NH2 HN- H HN NH2 HN HO PolyPeptide GROUP THE ULTIMATE PEPTIDE PARTNER